Synthesis, Structure, and Study of the Cytotoxic Activity of Zinc(II) Complex with 5-Benzyltetrazole and 1,10-Phenanthroline

E. A. Ermakova; Ермакова Е. А.; Yu. A. Golubeva; Голубева Ю. А.; K. S. Smirnova; Смирнова К. С.; L. S. Klyushova; Клюшова Л. С.; I. V. El’tsov; Ельцов И. В.; E. V. Lider; Лидер Е. В.

doi:10.31857/S0132344X22600631

Synthesis, Structure, and Study of the Cytotoxic Activity of Zinc(II) Complex with 5-Benzyltetrazole and 1,10-Phenanthroline

作者: Ermakova E.A.¹, Golubeva Y.A.¹, Smirnova K.S.¹, Klyushova L.S.², El’tsov I.V.³, Lider E.V.¹
隶属关系:
1. Nikolaev Institute of Inorganic Chemistry, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russia
2. Research Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia
3. Novosibirsk National Research State University, Novosibirsk, Russia
期: 卷 49, 编号 9 (2023)
页面: 582-589
栏目: Articles
URL: https://vietnamjournal.ru/0132-344X/article/view/667484
DOI: https://doi.org/10.31857/S0132344X22600631
EDN: https://elibrary.ru/WAENNY
ID: 667484

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅或者付费存取

详细
作者简介
参考
补充文件
统计

详细

The complex [Zn(Phen)(H2O)L2] (I), where HL is 5-benzyltetrazole, Phen is 1,10-phenanthroline,
was synthesized. The compound was characterized by standard physicochemical methods (elemental
analysis, powder X-ray diffraction, IR spectroscopy). According to X-ray diffraction data (CCDC no.
2220597), zinc coordination environment in the crystal structure of I corresponds to a distorted trigonal
bipyramid. The ligand HL is monodentate and is coordinated via tetrazolate ring nitrogen. The stability of
complex I was studied by NMR spectroscopy in DMSO. The cytotoxic properties of the compound were
assessed against HepG-2 (hepatocellular carcinoma) and MRC-5 (noncancerous human fibroblasts) cells.
Complex I exhibits weak cytotoxic properties in the studied concentration range (1–100 μM).

关键词

zinc, crystal structure, cytotoxicity, MRC-5

参考

Vallee B.L., Auld D.S. // Proc. Natl. Acad. Sci. USA. 1990. V. 87. № 1. P. 220.
Ostrovskii V.A., Koldobskii G.I., Trifonov, R.E. Comprehensive Heterocyclic Chemistry III / Eds. Elsevier. Oxford, 2008. P. 259.
Ostrovskii V.A., Trifonov R.E., Popova E.A. // Russ. Chem. Bull. 2012. V. 61. № 4. P. 768.
Dofe V.S., Sarkate A.P., Kathwate S.H. et al. // Heterocycl. Commun. 2017. V. 23. № 4. P. 325.
Chohan Z.H., Supuran C.T., Scozzafava A. // J. Enzyme Inhib. Med. Chem. 2008. V. 19. № 1. P. 79.
Brand S.R., Degenhardt T.P., Person K. et al. // Am. J. Obstet. Gynecol. 2017. V. 217. № 6. P. 715.
Hoekstra W.J., Hargrove T.Y., Wawrzak Z. et al. // Antimicrob. Agents Chemother. 2015. V. 60. № 2. P. 1058.
Gonzalez-Lara M.F., Sifuentes-Osornio J., Ostrosky-Zeichner L. // Drugs. 2017. V. 77. № 14. P. 1505–1518.
Warrilow A.G.S., Parker J.E., Price C.L. et al. // Antimicrob. Agents Chemother. 2016. V. 60. № 8. P. 4530–4538.
May B.C.H., Abell A.D. // Tetrahedron Lett. 2001. V. 42. № 33. P. 5641.
May B.C.H., Abell A.D. // Perkin Trans. 2002. V. 2. № 2. P. 172.
Popova E.A., Protas A.V., Trifonov R.E. // Anticancer. Agents Med. Chem. 2017. V. 17. № 14. P. 1856.
Romagnoli R., Baraldi P.G., Salvador M.K. et al. // J. Med. Chem. 2012. V. 55. № 1. P. 475.
Jedhe G.S., Paul D., Gonnade R.G. et al. // Bioorganic Med. Chem. Lett. 2013. V. 23. № 16. P. 4680.
Beale T.M., Allwood D.M., Bender A. et al. // ACS Med. Chem. Lett. 2012. V. 3. № 3. P. 177.
Subba Rao A.V., Swapna K., Shaik S.P. et al. // Bioorganic Med. Chem. 2017. V. 25. № 3. P. 977.
Mohite P.B., Bhaskar V.H. // Int. J. PharmTech Res. 2011. V. 3. № 3. P. 1557.
Eremina J.A., Smirnova K.S., Klyushova L.S. et al. // J. Mol. Struct. 2021. V. 1245. P. 131024.
Bruker Apex3 Software Suite: Apex3, SADABS-2016/2 and SAINT. Version 2018.7-2. Madison (WI, USA): Bruker AXS Inc., 2017.
Sheldrick G.M. // Acta Crystallogr. A. 2015. V. 71. P. 3.
Sheldrick G.M. // Acta Crystallogr. C. 2015. V. 71. P. 3.